Exchange: NASDAQ·Updated 07:30 PM EST

ENTA News

News
all
press releases
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to Strong Sell at Wall Street Zen
Wall Street Zen downgraded Enanta Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to Strong Sell at Wall Street Zen
Wall Street Zen downgraded Enanta Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
More News
JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $19.00 to $17.00 and set an "overweight" rating on the stock in a research note on Friday...
MarketBeat
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.41% and -10.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2026. During fiscal 2026 we made...
Business Wire
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +6.25% and -18.31%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Immatics (IMTX) delivered earnings and revenue surprises of -18.37% and -22.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kamada (KMDA) delivered earnings and revenue surprises of +7.69% and -2.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -64.71% and +1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies...
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027...
Business Wire

Advertisement|Remove ads.